Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Growth in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 23,175 shares, a growth of 28.6% from the February 26th total of 18,020 shares. Based on an average daily trading volume, of 120,867 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the shares of the stock are sold short.

Hedge Funds Weigh In On Xtant Medical

Institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new stake in Xtant Medical in the 2nd quarter valued at $26,000. Mink Brook Asset Management LLC lifted its stake in Xtant Medical by 125.8% in the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after purchasing an additional 60,997 shares in the last quarter. Tradition Wealth Management LLC bought a new position in shares of Xtant Medical during the 4th quarter valued at about $79,000. Wiregrass Investment Management LLC bought a new position in shares of Xtant Medical during the 4th quarter valued at about $81,000. Finally, Vanguard Group Inc. grew its position in shares of Xtant Medical by 4.6% during the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after purchasing an additional 104,159 shares in the last quarter. 69.33% of the stock is owned by hedge funds and other institutional investors.

Xtant Medical Stock Performance

Shares of XTNT opened at $0.55 on Monday. The firm has a market cap of $77.42 million, a P/E ratio of 55.36 and a beta of -0.30. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.21 and a quick ratio of 1.06. Xtant Medical has a 1 year low of $0.34 and a 1 year high of $0.95. The company has a 50 day simple moving average of $0.60 and a two-hundred day simple moving average of $0.67.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum reissued a “buy” rating on shares of Xtant Medical in a report on Wednesday, March 18th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $1.50.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.